Edison Inv. Res Comments on Nicox S.A.’s FY2022 Earnings (OTCMKTS:NICXF)

Nicox S.A. (OTCMKTS:NICXFGet Rating) – Equities researchers at Edison Inv. Res cut their FY2022 earnings estimates for shares of Nicox in a research note issued to investors on Thursday, May 19th. Edison Inv. Res analyst P. Hemami now anticipates that the company will post earnings of ($0.45) per share for the year, down from their previous estimate of ($0.39). Edison Inv. Res also issued estimates for Nicox’s FY2023 earnings at ($0.46) EPS and FY2024 earnings at ($0.79) EPS.

Separately, Zacks Investment Research raised Nicox from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Thursday.

NICXF opened at $1.77 on Monday. The business’s 50-day simple moving average is $1.94 and its 200 day simple moving average is $2.60. Nicox has a 52-week low of $1.77 and a 52-week high of $5.10.

About Nicox (Get Rating)

Nicox SA operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial.

Featured Articles

Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.